Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
2004 1
2006 24
2008 2
2009 3
2010 8
2011 3
2012 10
2013 11
2014 10
2015 8
2016 4
2017 3
2018 11
2019 8
2020 1
2021 9
2022 9
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 29999702

101 results

Results by year

Filters applied: . Clear all
Page 1
Mipomersen.
[No authors listed] [No authors listed] 2022 Sep 19. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2022 Sep 19. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999702 Free Books & Documents. Review.
Mipomersen sodium: first global approval.
Hair P, Cameron F, McKeage K. Hair P, et al. Drugs. 2013 Apr;73(5):487-93. doi: 10.1007/s40265-013-0042-2. Drugs. 2013. PMID: 23564617 Review.
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M. Thomas GS, et al. J Am Coll Cardiol. 2013 Dec 10;62(23):2178-84. doi: 10.1016/j.jacc.2013.07.081. Epub 2013 Sep 4. J Am Coll Cardiol. 2013. PMID: 24013058 Free article. Clinical Trial.
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, Lachmann RH, Gaudet D, Tan JL, Chasan-Taber S, Tribble DL, Flaim JD, Crooke ST. Raal FJ, et al. Lancet. 2010 Mar 20;375(9719):998-1006. doi: 10.1016/S0140-6736(10)60284-X. Lancet. 2010. PMID: 20227758 Clinical Trial.
101 results